This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Tipranks - Fri May 1, 10:36AM CDT

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation today and set a price target of $16.00.

Claim 55% Off TipRanks

Stephan covers the Healthcare sector, focusing on stocks such as TransMedics Group, Glaukos, and Alphatec Holdings. According to TipRanks, Stephan has an average return of 2.1% and a 40.00% success rate on recommended stocks.

In addition to Stifel Nicolaus, Bausch + Lomb Corporation also received a Hold from Barclays’s Matt Miksic in a report issued today. However, on the same day, Citi maintained a Buy rating on Bausch + Lomb Corporation (NYSE: BLCO).

Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.24 billion and a GAAP net loss of $71 million. In comparison, last year the company earned a revenue of $1.14 billion and had a GAAP net loss of $212 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Last month, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.